ArticleFrontiers in bioengineering and biotechnology2026
Development of electrochemiluminescence immunochromatographic test strips for dengue virus.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dengue virus (DENV) infection poses a serious threat to global public health. Rapid and sensitive point-of-care diagnostic methods are urgently needed for early detection and epidemic control. Methods: The dengue virus monoclonal antibody NS1-McAb1# was labeled as the labeled antibody and sprayed onto the binding pad using ruthenium tripyridine as the signal probe, and the dengue virus monoclonal antibody DN-REAB-G2-006 was fixed on the detection pad as the capture antibody. To mitigate potential interference from other substances in the sample, the sample pad and conjugate pad was pretreated with a solution containing heterophilic blocking reagent, and Elecsys buffer was selected as the optimal co-reactant. After dropping the sample onto the sample pad, chromatography and immunoreaction were performed sequentially. Then, cyclic voltammetry scanning was carried out in the test zone at a rate of 0.1 V/s for electrochemiluminescence (ECL) detection. A novel detection method was established by optimizing various parameters. Result: The ruthenium-labeled antibody was prepared by reacting Ru-NHS ester with NS1-McAb1# at a molar ratio of 50:1 for 10 h. Elecsys Buffer was selected as the co-reactant, with a sample-to-buffer volume ratio of 2:1. Whatman AE 100 membrane was used as the detection pad with a length set to 15 mm. The concentration ratio of labeled antibody to capture antibody was 1:2. The chromatographic time after sample loading was 10 min. Under these optimized conditions, the detection method achieved a minimum detection limit of 20.76 pg/mL, exhibited good specificity, with an intra-assay repeatability coefficient of variation of 4%, a storage stability coefficient of variation of 0.83%, and an inter-assay stability coefficient of variation of 0.81%. Clinical sample validation showed a Discussion: The developed ECLIA test strip provides a portable, rapid, and sensitive detection method for DENV, with potential applications in on-site testing across multiple scenarios. Although preliminary clinical evaluation showed acceptable concordance with nucleic acid testing, further large-scale validation using diverse clinical specimens is necessary to fully establish its diagnostic utility in real-world settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.